index - Myopathies inflammatoires & thérapies innovantes ciblées Accéder directement au contenu

Dernières publications

Chiffres clés

123 Publications avec texte intégral

Open Access

53 %

Mots clés

Anticorps spécifique des myosites AAV humoral immunity Muscle Myositis and muscle disease Abnormal movement IMNM Dermatomyositis Antiphospholipid syndrome Antisynthétase Antisynthetase Inclusion body myositis Autoantibodies Middle Aged Immune checkpoint inhibitors AAV vectors Interferon Biomarqueurs Inborn errors of metabolism AAV antibody Gene therapy Myopathy Amyotrophy Inflammation Female Adverse drug reactions Anti‐mitochondrial antibodies Data integration Lysosomal storage diseases Machine learning Cytokines Multidisciplinarity Anti-interleukin-6 Auto‐antibodies Mass cytometry Interstitial lung disease Adeno-associated virus vector DM Idiopathic inflammatory myopathies Anti-IgE IgG AAV Prognosis Antibody responses Adeno-associated virus Acute Kidney Injury/epidemiology/etiology Biopsy Assisted communication devices Dependovirus/genetics/immunology Case reports Myocarditis Aldostérone Adult Polymyositis Humans Analyses multidimensionnelles AAV vector Aged Cancer Bioelectrical impedance analysis Cardio-oncology Anti-agalsidase antibodies Autoimmunity Immunotherapy Adolescence Agalsidase Pharmacology IBM Anémie hémolytique B cell homeostasis Systems biology Antibodies Biomarker Adjudication Auto-antibodies Animals Acid-alpha-glucosidase Auto-immunité Anti-drug antibodies Fabry disease Outcome measures Deep immune profiling Arthritis Male Myositis B-lymphocyte Inflammatory myopathy Biomarkers Antisynthetase syndrome Anti-MDA5 autoantibodies Amyotrophic lateral sclerosis Autoantibody Anti-Mi2 Anti-synthetase syndrome Autoimmune diseases Adeno-associated vector COVID-19 Skeletal muscle Active Sphingosine-1-phosphate Aldosterone Anticorps anti-agalsidase